PA
OMIC

Parallel Advisors’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Parallel Advisors’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11
Closed -$1K – 3553
2022
Q3 		$1K Buy
+11
New +$1.15K ﹤0.01% 3070

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's OMIC Position: Q4 2022 in Review

Parallel Advisors sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q4 2022, closing a stake of 11 shares — an estimated $1K sold.

Parallel Advisors first reported a position in OMIC in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 80 funds tracked by Wall St. Rank hold OMIC as of Q4 2022.

  • Parallel Advisors reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Parallel Advisors sold 11 Singular Genomics Systems, Inc. Common Stock shares in Q4 2022, an estimated $1K.
  • Parallel Advisors first reported a position in Singular Genomics Systems, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Parallel Advisors's Singular Genomics Systems, Inc. Common Stock position peaked at $1K in Q3 2022.
  • 80 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.